MedTrace Logo

Nivolumab and AVD in Early-stage Unfavorable Classical Hodgkin Lymphoma

NCT03004833 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 110

Last updated 2025-04-03

No results posted yet for this study

Summary

The aim of the trial is to improve first-line treatment for early unfavorable cHL by introduction of the anti-PD-1 antibody Nivolumab with a truncated standard chemotherapy (AVD).

The primary objective is to show efficacy of the two experimental treatment strategies. Secondary objectives are to further evaluate efficacy, show safety and feasibility and perform correlative studies.

Conditions

  • Classical Hodgkin Lymphoma

Interventions

DRUG

Nivolumab

Infusion of Nivolumab

DRUG

Adriamycin

Infusion of Adriamycin

DRUG

Vinblastine

Infusion of Vinblastine

DRUG

Dacarbazine

Infusion of Dacarbazine

Sponsors & Collaborators

  • University of Cologne

    lead OTHER

Principal Investigators

  • Andreas Engert, Prof. · University of Cologne, I. Dept. of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-02-21
Primary Completion
2022-08-22
Completion
2022-08-22

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03004833 on ClinicalTrials.gov